Department of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai, China.
Int J Cancer. 2022 Jun 1;150(11):1745-1759. doi: 10.1002/ijc.33918. Epub 2022 Jan 12.
Poly(ADP-ribose) polymerase (PARP) enzymes, especially PARP1, play important roles in the DNA damage response and in the maintenance of genome stability, which makes PARPis a classic synthetic lethal therapy for BRCA-deficient tumors. Conventional mechanisms suggest that PARPis exert their effects via catalytic inhibition and PARP-DNA trapping. Recently, PARP1 has been found to play a role in the immune modulation of tumors. The blockade of PARP1 is able to induce innate immunity through a series of molecular mechanisms, thus allowing the prediction of the feasibility of PARPis combined with immune agents in the treatment of tumors. PARPis combined with immunomodulators may have a stronger tumor suppressive effect on inhibiting tumor growth and blocking immune escape.
聚(ADP-核糖)聚合酶(PARP)酶,特别是 PARP1,在 DNA 损伤反应和基因组稳定性维持中发挥重要作用,这使得 PARPi 成为 BRCA 缺陷型肿瘤的经典合成致死治疗方法。传统机制表明,PARPi 通过催化抑制和 PARP-DNA 捕获发挥作用。最近,PARP1 被发现在肿瘤的免疫调节中发挥作用。PARP1 的阻断能够通过一系列分子机制诱导先天免疫,从而可以预测 PARPi 与免疫制剂联合治疗肿瘤的可行性。PARPi 与免疫调节剂联合使用可能对抑制肿瘤生长和阻断免疫逃逸具有更强的肿瘤抑制作用。